Evidence map›Paper›PMID 27152687›Full record

ReviewPain2016

Patient phenotyping in clinical trials of chronic pain treatments: IMMPACT recommendations.

Robert R Edwards, Robert H Dworkin, Dennis C Turk, Martin S Angst, Raymond Dionne, Roy Freeman, Per Hansson, Simon Haroutounian, Lars Arendt-Nielsen, Nadine Attal and 28 more

2 registry-linked trialsAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pain, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 243 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
243citing papers in PubMed, 10 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05025787 phase2completednot on this mapstarted 2021, after this paper: background citation

EN20-01: A 24 Week Study to Evaluate the Safety and Efficacy of CNTX-6970 in Subjects With Moderate to Severe Knee Osteoarthritis Pain.

TypeinterventionalSponsorMaurizio Fava, MDRan2021 to 2024Enrolled55ConditionsKnee OsteoarthritisArmsCNTX-6970, Placebo
NCT07081737 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

The Future of Pain Management: Can Person-centred and Precision AI-Based Decision Support Enhance Interdisciplinary Rehabilitation for Chronic Pain?

TypeinterventionalSponsorBjorn AngRan2026 to 2029Enrolled400ConditionsPain, Chronic, Chronic Pain, Widespread, Pain ManagementArmsInterdisciplinary treatment (IDT) + Clinical Decision Support System (CDSS), Interdisciplinary treatment (IDT)
3 · Its place in the literature

Who cites it

243 citing papers in PubMed, 10 syntheses or guidelines pooled it.

  1. Pooled it
  2. Guideline
  3. Guideline
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Journal of dental research · 2021
    Trial
  18. Trial
  19. Trial
  20. Trial

183 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

38 authors.

Robert R EdwardsHarvard Medical School, Boston, MA, USA.
Robert H DworkinUniversity of Rochester, Rochester, NY, USA.
Dennis C TurkUniversity of Washington, Seattle, WA, USA.
Martin S AngstStanford University, Palo Alto, CA, USA.
Raymond DionneEast Carolina University, Greenville, NC, USA.
Roy FreemanHarvard Medical School, Boston, MA, USA.
Per HanssonOslo University Hospital, Oslo, Norway and Karolinska Institute, Stockholm, Sweden.
Simon HaroutounianWashington University, St. Louis, MO, USA.
Lars Arendt-NielsenAalborg University, Aalborg, Denmark.
Nadine AttalHôpital Ambroise Paré, APHP and INSERM U 987, Boulogne-Billancourt, France and University Versailles Saint Quentin, Versailles, France.
Ralf BaronUniversity of Kiel, Kiel, Germany.
Joanna BrellMetroHealth Medical Center, Cleveland, OH, USA.
Shay BujanoverDepomed, Newark, CA, USA.
Laurie B BurkeLORA Group, LLC, Royal Oak, MD, USA.
Daniel CarrTufts University, Boston, MA, USA.
Amy S ChappellEli Lilly, Indianapolis IN, USA.
Penney CowanAmerican Chronic Pain Association, Rocklin, CA, USA.
Mila EtropolskiJohnson and Johnson, Titusville, NJ, USA.
Roger B FillingimUniversity of Florida, Gainesville, FL, USA.
Jennifer S GewandterUniversity of Rochester, Rochester, NY, USA.
Nathaniel P KatzTufts University, Boston, MA, USA.
Ernest A KopeckyCollegium Pharmaceutical, Inc., Canton, MA, USA.
John D MarkmanUniversity of Rochester, Rochester, NY, USA.
George NomikosAstellas Pharma, Northbrook, IL, USA.
Linda PorterNational Institutes of Health, Bethesda, MD, USA.
Bob A RappaportArlington, VA, USA.
Andrew S C RiceImperial College, London, United Kingdom.
Joseph M ScavonePfizer, Groton, CT, USA.
Joachim ScholzColumbia University, New York, NY, USA.
Lee S SimonSDG LLC, Cambridge, MA, USA.
Shannon M SmithUniversity of Rochester, Rochester, NY, USA.
Jeffrey TobiasJazz Pharmaceuticals, Palo Alto, CA, USA.
Tina TockarshewskyCeres Consulting, Fort Montgomery, NY, USA.
Christine VeasleyChronic Pain Research Alliance, North Kingstown, RI, USA.
Mark VersavelZalicus, Cambridge, MA, USA.
Ajay D WasanUniversity of Pittsburgh, Pittsburgh, PA, USA.
Warren WenPurdue Pharma, Stamford, CT, USA.
David YarnitskyRambam Health Care Campus and Technion Faculty of Medicine, Haifa, Israel.

Funding

Brain Mechanisms Underlying CBT-Related Reductions in FibromyalgiaR01AR064367 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI EDWARDS, ROBERT R, NAPADOW, VITALY · 2014 to 2018
$4.0M
Biobehavioral Risk Factors for Persistent Pain following Total Knee ArthroplastyR01AG034982 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI EDWARDS, ROBERT R · 2010 to 2014
$3.2M
Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) Public-Private PartnershipU01FD005936 · FDA · UNIVERSITY OF ROCHESTER · PI DWORKIN, ROBERT H · 2016 to 2020
$2.5M
FDA HHS U01 FD005936NIAMS NIH HHS R01 AR064367NIA NIH HHS R01 AG034982
6 · The paper itself

Abstract

There is tremendous interpatient variability in the response to analgesic therapy (even for efficacious treatments), which can be the source of great frustration in clinical practice. This has led to calls for "precision medicine" or personalized pain therapeutics (ie, empirically based algorithms that determine the optimal treatments, or treatment combinations, for individual patients) that would presumably improve both the clinical care of patients with pain and the success rates for putative analgesic drugs in phase 2 and 3 clinical trials. However, before implementing this approach, the characteristics of individual patients or subgroups of patients that increase or decrease the response to a specific treatment need to be identified. The challenge is to identify the measurable phenotypic characteristics of patients that are most predictive of individual variation in analgesic treatment outcomes, and the measurement tools that are best suited to evaluate these characteristics. In this article, we present evidence on the most promising of these phenotypic characteristics for use in future research, including psychosocial factors, symptom characteristics, sleep patterns, responses to noxious stimulation, endogenous pain-modulatory processes, and response to pharmacologic challenge. We provide evidence-based recommendations for core phenotyping domains and recommend measures of each domain.

Indexed as

Treatment OutcomeAnalgesicsChronic PainClinical Trials as TopicHumansPain MeasurementPhenotypeAnalgesics

Identifiers

PMID27152687
PMCPMC5965275

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.